Jameson Legal














McDermott Will & Emery Represents Innate Pharma in Acquisition of Anti-C5aR

08 Jun 2017

McDermott Will & Emery represented Innate Pharma, a clinical-stage biotechnology company, in its purchase of Anti-C5aR from Novo Nordisk A/S, a global healthcare company.

According the terms of the agreement, Novo Nordisk A/S grants Innate Pharma full worldwide exclusive rights to develop and commercialize a first-in-class clinical-stage anti-C5aR antibody (IPH5401) representing a novel therapeutic approach in immuno-oncology.

Thanks to this operation, Innate Pharma strengthens its current immuno-oncology pipeline, in which IPH5401 is a strategic fit. IPH5401 adds a clinical-stage proprietary product that reinforces Innate Pharma’s position in the field of antibodies targeting the tumor microenvironment beyond the company’s activities in the adenosine pathway. Innate Pharma plans to start trials with IPH5401 in oncology in 2018. 

The McDermott team was led by corporate partners Emmanuelle Trombe and Bertrand Delafaye, and included corporate associate Marion Abecassis, tax partner Antoine Vergnat and tax associate Côme de Saint-Vincent. 

Innate Pharma was also advised by Linklaters, while Novo Nordisk A/S was represented by Baker McKenzie.

McDermott’s Life Sciences Group works with clients to structure collaborative arrangements among emerging life sciences companies, established pharmaceutical and biotech companies and researchers and research institutions. These arrangements range from licensing technology to and from academic medical centers, universities and other research institutions, to complex strategic alliances among life sciences companies to achieve varied financial, research and development, manufacturing and distribution objectives. The Firm’s long-term experience in advising pharmaceuticals and agrochemical companies on taxation issues allows us to devise structures and tax plans for life sciences companies who wish to be attractive partners or acquisition candidates for the pharmaceutical industry.

Matter Type
Asset Sale: Acquiror's Counsel
Healthcare, Life Sciences & Chemicals
News Category
Real Estate & Construction